Chekeni FB, Elliott MR, Sandilos JK et al.Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 467:863-867

Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia 22908, USA.
Nature (Impact Factor: 41.46). 10/2010; 467(7317):863-7. DOI: 10.1038/nature09413
Source: PubMed


Apoptotic cells release 'find-me' signals at the earliest stages of death to recruit phagocytes. The nucleotides ATP and UTP represent one class of find-me signals, but their mechanism of release is not known. Here, we identify the plasma membrane channel pannexin 1 (PANX1) as a mediator of find-me signal/nucleotide release from apoptotic cells. Pharmacological inhibition and siRNA-mediated knockdown of PANX1 led to decreased nucleotide release and monocyte recruitment by apoptotic cells. Conversely, PANX1 overexpression enhanced nucleotide release from apoptotic cells and phagocyte recruitment. Patch-clamp recordings showed that PANX1 was basally inactive, and that induction of PANX1 currents occurred only during apoptosis. Mechanistically, PANX1 itself was a target of effector caspases (caspases 3 and 7), and a specific caspase-cleavage site within PANX1 was essential for PANX1 function during apoptosis. Expression of truncated PANX1 (at the putative caspase cleavage site) resulted in a constitutively open channel. PANX1 was also important for the 'selective' plasma membrane permeability of early apoptotic cells to specific dyes. Collectively, these data identify PANX1 as a plasma membrane channel mediating the regulated release of find-me signals and selective plasma membrane permeability during apoptosis, and a new mechanism of PANX1 activation by caspases.

Download full-text


Available from: Jason M Kinchen,
  • Source
    • "Apoptotic cell death develops due to caspase-mediated events and disappearance of membrane ion gradients [43] [49]. It is also suspected that the negative feedback involves "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purinergic signaling modulates dopaminergic neurotransmission in health and disease. Classically adenosine A1 and A2A receptors have been considered key for the fine tune control of dopamine actions in the striatum, the main CNS motor control center. The main adenosine signaling mechanism is via the cAMP pathway but the future will tell whether calcium signaling is relevant in adenosinergic control of striatal function. Very relevant is the recent approval in Japan of the adenosine A2A receptor antagonist, istradefylline, for use in Parkinson's disease patients. Purine nucleotides are also regulators of striatal dopamine neurotransmission via P2 purinergic receptors. In parallel to the alpha-synuclein hypothesis of Parkinson's disease etiology, purinergic P2X1 receptors have been identified as mediators of accumulation of the Lewy-body enriched protein alpha-synuclein. Of note is the expression in striatum of purinergic-receptor-containing heteromers that are potential targets of anti-Parkinson's disease therapies and should be taken into account in drug discovery programs. Copyright © 2015. Published by Elsevier Ltd.
    Neuropharmacology 07/2015; DOI:10.1016/j.neuropharm.2015.07.024 · 5.11 Impact Factor
  • Source
    • "Externalized proteins, more or less linked to the membrane of the infected cell can provide an “eat me” signal to attracted phagocytes. When cells undergo immunogenic apoptosis, the release of ATP is a known “find me” signal to promote phagocytic clearance of those cells at a very early time point (46, 47). ATP is released by Pannexin channels and sensed by P2Y (2) purinergic receptors on monocytes to facilitate their attraction to the site of apoptotic cell death. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oncolytic virotherapy has shown impressive results in preclinical studies and first promising therapeutic outcomes in clinical trials as well. Since viruses are known for a long time as excellent vaccination agents, oncolytic viruses are now designed as novel anticancer agents combining the aspect of lysis-dependent cytoreductive activity with concomitant induction of antitumoral immune responses. Antitumoral immune activation by oncolytic virus infection of tumor tissue comprises both, immediate effects of innate immunity and also adaptive responses for long lasting antitumoral activity, which is regarded as the most prominent challenge in clinical oncology. To date, the complex effects of a viral tumor infection on the tumor microenvironment and the consequences for the tumor-infiltrating immune cell compartment are poorly understood. However, there is more and more evidence that a tumor infection by an oncolytic virus opens up a number of options for further immunomodulating interventions such as systemic chemotherapy, generic immunostimulating strategies, dendritic cell-based vaccines, and antigenic libraries to further support clinical efficacy of oncolytic virotherapy.
    Frontiers in Oncology 07/2014; 4:188. DOI:10.3389/fonc.2014.00188
  • Source
    • "Perhaps the best understood direct gating mechanism to date (at least at the molecular level) is Panx1 activation by direct caspase-3/7 cleavage of the c-terminus resulting in the removal of the last 45–50 amino acids (depending on species) [17], [24]–[25]. Gating by this mechanism is necessary for the release of ATP and possibly other small molecules during apoptosis, some of which may be used by macrophages as homing signals, aiding in the rapid clearance of apoptotic cells [17], [24], [26]. Mechanistically, the c-terminal peptide has been proposed to directly block the Panx1 pore by binding within the pore from the intracellular side of the channel [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Pannexin-1 (Panx1) channel is known to become activated under a variety of physiological conditions resulting in the release of medium-sized molecules such as ATP and amino acids from the cell. The detailed molecular mechanism of activation of the channel resulting in the opening of the Pannexin pore is poorly understood. The best-studied gating mechanism is caspase-3/7-mediated cleavage and truncation of the c-terminus. In the absence of caspase-cleavage, the c-terminal peptide maintains the channel in the closed state, possibly by directly plugging the pore from the intracellular side. We sought to understand in detail the part of the c-terminus necessary for this interaction by alanine-scanning and truncation mutagenesis of the c-terminal gating peptide. These experiments demonstrate that no single amino acid side-chain is necessary for this interaction. In fact, replacing blocks of 10-12 amino acids in different parts of the c-terminal peptide with alanines fails to disrupt the ability of the c-terminus to keep the channel closed. Surprisingly, even replacing the entire c-terminal gating peptide with a scrambled peptide of the same length maintains the interaction in some cases. Further analysis revealed that the interaction surface, while delocalized, is located within the amino-terminal two-thirds of the c-terminal peptide. Such a delocalized and potentially low-affinity interaction surface is allowed due to the high effective concentration of the c-terminal peptide near the inner vestibule of the pore and likely explains why this region is poorly conserved between species. This type of weak interaction with a tethered gating peptide may be required to maintain high-sensitivity to caspase-dependent activation.
    PLoS ONE 06/2014; 9(6):e99596. DOI:10.1371/journal.pone.0099596 · 3.23 Impact Factor
Show more